Summary. An immunochemical micromethod was designed to estimate total IgG and IgG sub-classes of anti-insulin antibodies in immunized diabetic patients. Insulin, immobilized on a solid phase, was allowed to react with serum samples containing anti-insulin antibodies. Bound anti-insulin IgG interacted with mouse monoclonal antibodies specific for total IgG or for each IgG isotype. The fixation of mouse monoclonal antibody was subsequently detected using a horseradish peroxidase-conjugated rabbit anti-mouse IgG in the presence of a chromogenic substrate. The test was standardized by an immunocapture assay utilizing coated rabbit anti-human IgG and known concentrations of purified human myelomatous proteins of each sub-class. Results of anti-insulin IgG and anti-insulin IgG sub-classes assay could therefore be expressed in ng equivalent myelomatous proteins per ml of serum. Analysis of serum samples from 24 insulin-immunized diabetic patients revealed a quasi absence of IgG2 anti-insulin antibodies and an increase of the relative abundance of the other three anti-insulin IgG isotypes. In our series, anti-insulin IgG1 was predominant, followed by IgG3 (in 17/24 patients) or IgG4 (in 7/24). Insulin immunization was deduced to be of polyclonal nature, the isotype pattern of which is not representative of the relative proportion of lgG sub-classes in whole normal serum.
Owing to the availability of monoclonal reagents specific for human IgG isotypes, the profile of the humoral immune response in man becomes more and more documented. IgG2 is the major component of antibodies against bacterial polysaccharides [1] , whereas IgG4 is predominant in immunization against coagulation factorVIII [2] . On the other hand, IgG1 and IgG3 are mostly responsible for anti-viral [3, 4] and anti-blood group responses [5, 6] . In most studies already reported, the distribution of IgG sub-classes carrying specific antibodies does not parallel that of isotypes in whole serum.
Since the physico-chemical and biological properties of the four human IgG isotypes are known to be different, the class and sub-class of antibody carrying immunoglobulins could be of clinical significance.
To our knowledge, the IgG sub-classes distribution of anti-insulin (AI) antibodies has never been characterized in man. Yet, animal experiments suggest that the sub-class of IgG may play an important role in determining the rate of immune complexes (IC) clearance in vivo. In the guinea pig, two IgG sub-classes can be identified and purified [7] : IgG1, which does not activate complement and is not cytophilic, and IgG2, which binds Clq and specific Fc receptors on macrophages. These two sub-classes were purified and utilized to form immune complexes with 123-I-insulin. In the rat, IgG2 IC rapidly disappeared from the plasma and were taken up by the liver and, to a much lower extent, by the spleen. By contrast, IC formed with IgG1 remained in plasma compartment and behaved as blood pooling agents [8] .
The above considerations led us to design a method to identify AI IgG sub-classes and to estimate their plasma concentration in man in order to study the immunization pattern of diabetic patients and define a possible correlation between this pattern and clinical course.
The present paper reports the results obtained by analysis of 24 sera from immunized diabetic patients using a highly sensitive assay based on the principle of ELISA [91.
Materials and methods

Materials
The human sera analyzed by this ELISA method were collected from insulin-immunized diabetic patients, selected on the basis of their Methods reactivity in the radioimmunoassay [10] Seventy-five ~tl per well of bovine insulin dissolved in coating buffer at a concentration of 13.3 p~g/ml were left overnight at 4 °C or alternatively 2 h at 37 °C. After three washings, the plates were filled with washing buffer and allowed to stand 30 min at room temperature in order to saturate the remaining polystyrene reactive sites.
Fifty ~tl of patients' sera previously diluted 1/5 were tested in serial two-fold dilutions from well 2 to 12 (i/5-1/5, 120) and incubated 2 h at 37 °C. After three washings, 50 ~tl of optimal dilutions of monoclonal reagents were allowed to react for 2 h at 37 °C. The excess of monoclonal reagent was eliminated by three further washings, and the specific antigen-antibody complex was revealed using peroxidase conjugated rabbit anti-mouse immunoglobulins at a 1/250 dilution as recommended by the manufacturer and confirmed by our own experience. After a 1-h incubation and four washings with tap water, the substrate solution was added (50 Id/well). The enzymic activity was stopped after 45 min by addition of 150 Ixl 2 N H2SO4.
Blank values (O. D. Blank) were obtained from column 1, which received all reagents but human serum or myelomatous protein.
Sera from 21 healthy blood donors were similarly tested and served as negative controls in order to determine the magnitude of optical density due to non specific binding.
Standardization of the assay was performed with purified myelomatous human IgG at known concentration in an immuno capture assay [11] : In this assay, plates previously coated with 75 ~tl of the optimal dilution of rabbit Ig anti-human IgG (7/-chain specific), received, 50 ~tl of 11 two-fold dilutions of each purified IgG isotype at a known initial concentration (2.000 -2 ng/ml). The subsequent steps of the standardization assay were identical to those above mentionned.
Semi-quantitative estimation: Optical density values of standards and samples were plotted on a graph as a function of the logarithm of dilution. From the calibration curves obtained with known amounts of purified isotypes, a concentration unit (Cu) was defined as the Ig concentration giving a AOD = 0.2 (AOD = OD sample -OD Blank) in the test conditions. This Cu was measured for each isotype/antiisotype system individually so that the following formula could be applied to each sub-class assay:
where C = concentration of anti-insulin immunoglobulin G1 (G2, G3 or G4) in ng per ml of serum; cu = concentration of myelomatous protein (in ng/ml) giving a zlO. D. = 0.2, Dil. = dilution of the tested serum sample giving AO. D. = 0.2 
Reciprocal dilution
Results
Coating conditions were optimized to obtain maximal sensitivity for the detection of anti-insulin antibodies. At first, efficiency of coating was improved by raising the pH of coating solutions from 7.4 to 9.6. On the other hand, using HPLC-prepared 125-I TyrA 14-bovine insulin, we measured the percentage of insulin really adsorbed from various insulin concentrations in the coat- (Table 1) , a result consistent with that of Nell et al. [12] . As illustrated in Figure 1 , ELISA curves obtained with the same AI serum and varying amounts of coated antigen exhibited highest optical density values -and consequently, the best sensitivity -in the range of 6.67-13.3 ~tg/ml coated insulin per well. An insulin concentration of 13.3 ~tg/ml in coating buffer was therefore used through all assays.
Optimal dilutions of both monoclonal and polyclonal reagents were established in series of standard three-way chequerboard titrations in order to determine the greatest dilution of each reagent still detecting the smallest concentrations of target antigens. We deduced that monoclonal anti-IgG, anti-IgG1, anti-IgG2, antiIgG3 and anti-IgG4 could be respectively utilized at dilutions: 1/4,000, 1/1,000, 1/500, 1/2,000 and 1/4,000.
Similarly, optimal dilution of the polyclonal RAHIgG utilized for coating in the standardization assay was found to be 1/4,000.
It must be mentioned that we encountered an important problem of cross-reaction between rabbit antihuman IgG and mouse monoclonal antibodies. This made it necessary to further purify RAH-IgG by affinity chromatography with mouse IgG covalently coupled to Sepharose 4B (Pharmacia, Uppsala, Sweden). Figure 2A , B illustrates typical patterns obtained when testing serum samples of insulin-immunized diabetic patients: in the two cases shown, IgG1 was predominant, whereas the second most abundant subclasses were respectively IgG3 (2A) and IgG4 (2B). The standard curves obtained with serial dilutions of myelomatous proteins are shown in Figure 4 . Satisfactory standard curves were obtained for IgG1, IgG3 and IgG4, but not for IgG2. The strong cross-reaction between RAH-IgG and monoclonal anti-IgG2 persisted after affinity chromatography and was also encountered with the other anti-IgG2 monoclonal antibodies we tested: anti-IgG2 from Seward (BAM14, clone GOM 2) and from Bio-Yeda (6010-1, Rehovot, Israel). Because of this persistent cross-reaction, IgG2 were detectable in the serum of patients but not quantifiable by the immuno capture assay. On the contrary, the sensitivity limit of the assays for IgG1, IgG3, IgG4 and total IgG was respectively: 8.9 ng/ml, 12.4ng/ml, 6.3 ng/ml and 4.5 ng/ml. The lack of accuracy in IgG2 measurements is one of the reasons why the presently described test was qualified as semi-quantitative.
Inter and intra assay reproducibility was assessed with two different sera ( Table 2 ). At the threshold of A O. D. = 0.2, the average coefficient of variation was 20.4% (range from 10.3 to 41.9%), and this rather high value provides a second reason for the assay to be considered as semi-quantitative.
The results obtained with a series of 24 insulin immunized diabetic patients are shown in Table 3 . They are expressed in ng equivalent myelomatous protein per ml of serum according to the formula described in the method section. In this table, "zero" indicates that O. D. values obtained with a given serum were not significantly different from blanks, and "traces" (TR) means that O.D. in the presence of serum sample was lower than 0.2 even at initial serum dilution.
All patients presented IgG1 AI antibodies and, in all cases, IgG1 was the predominant anti-insulin IgG subclass. In our series, the mean concentration of IgG1 AI was found equal to 3,980 _ 4,334 ng equivalent myelomatous protein per ml of serum (mean_+ S.D.). On the other hand, IgG2 AI was absent or present in trace amount only. Measureable levels of A1 IgG3 and IgG4 were found: (541 _+ 625) and (286 + 452) ng equivalent myeloma protein per ml respectively. It is interesting to note that AI IgG3 were more abundant than IgG4 in 17 out of 24 patients (i. e. in 70% of cases), whereas an inverse pattern was observed in 7/24patients (30%). Some patients lacked IgG3 AI For each patient, the sum of IgG1, 3 and 4 was calculated and taken as 100% value in order to assess the relative abundance of each IgG sub-class implicated in AI immune response. On the average, the relative participation of anti-insulin IgG sub-class was respectively 81% for IgG1, 12% for IgG3 and 7% for IgG4. (Table 3) . As shown by Figure5, we observed a correlation (r2 = 0.928) between the sum of IgG sub-classes (calculated) and total IgG as experimentally determined in an assay utilizing anti-), chain reagent.
Discussion
Immunosorbent assays have already been applied to the detection of anti-insulin IgG antibodies using either enzyme conjugated anti-human IgG reagents [13] [14] [15] or 125-I-protein A [10, 16] .
In order to detect individually each IgG sub-class, we engaged monoclonal antibodies specific for each isotype in a four step procedure. This method offers the advantage of increasing the test sensitivity and specificity. Indeed, Moudallal et al. [17] demonstrated that multiplying the number of immunological layers of sandwich tests results in a significant enhancement of sensitivity. Furthermore, owing to the properties of antiisotypic monoclonal antibodies, only one epitope is recognized so that no cross-reaction can occur.
This ELISA assay allows a specific detection of AI IgG antibodies, since no reaction was observed with normal sera.
The assay of AI IgG sub-classes described in this report should be regarded as semi-quantitative rather than quantitative for several reasons. We know that optical densities are related to the amount of human IgG bound to immobilized insulin, but we do not know to what extent these detectable IgGs represent exhaustively or not all circulating AI antibodies. Several parameters, some of them being hardly controllable, may interfere and prevent full detection. The serum of insulin immunized diabetic patients contains free antibodies, but also insulin-anti-insulin immune complexes. Some of these complexes probably react with coated insulin, and others partially or totally escape detection. Pretreatment of serum with acid (pH 2.8), charcoal, chaotropic agents or a combination of them could have been added as a preliminary step but, to our knowledge, these extraction methods [18] dissociate mainly immune complexes involving weak affinity antibodies and introduce an error in re-establishing the original volume. Therefore, the amount of detectable human anti-insulin IgG sub-classes depends not only upon the proportion of free antibodies but also upon the potential dissociation of immune complexes.
An additional potential difficulty of this assay stems from the fact that several anti-insulin sub-classes are present in most sera. Thus, each sub-class competes with the others for binding to the immobilized ligand. As a consequence, the amount of insulin available for binding will be influenced by the proportion of each 725 isotype, the others acting as competitors. It is therefore conceivable that in hyperimmunized patients, a poorly represented anti-insulin IgG sub-class will be partially or even fully masked by the most abundant one.
Another point is the choice of appropriate standards. Since human specific anti-insulin IgG isotypes have not yet been purified, we used an immuno capture assay with RAH-IgG coated plates and human myelomatous protein of each sub-class. Since the crossreaction between anti-IgG2 monoclonals and coated RAH-IgG persisted even after affinity purification, standardization of IgG2 sub-class was unfortunately not possible. Nevertheless, we can conclude from our data that this isotype was generally absent or present in amount not exceeding 0.2 lxg/ml in the present series of immunized patients.
Despite the fact that the method is semi-quantitative, it is interesting to note that the sum of sub-classes was correlated to total anti-insulin IgG.
The relative abundance of anti-insulin IgG subclasses differs from their proportion in normal serum, particularly with regard to IgG2 which are lacking. Some immunogenic proteins and glycoproteins are known to preferentially stimulate IgG1 and IgG3 subclasses rather than IgG2 and IgG4. This is, for example, the case for most blood group antigens and especially the Rhesus (D) antigen. On the other hand, bacterial wall polysaccharides have been described to elicit an almost pure IgG2 humoral response. Imbalanced repartition of specific IgG antibodies is therefore not necessarily surprising. It may be speculated that insulin induces a specific pattern of response characterized by a lack of IgG2 production.
In classical conditions, patients are challenged with antigen for a short period of time (vaccination, transfusion, infection). In insulin-treated patients, the antigen is daily administered so that the clearance rate of antiinsulin IgG sub-class probably reflects that of immune complexes rather than that of free circulating antibodies.
Aside from insulin-dependent diabetes, haemophilia is another disease in the course of which a protein is frequently administered. It is worth noting that the profile of anti-factor VIII immunization also shows an abnormal IgG distribution, since it is characterized by a higher than expected abundance of IgG4 [2, 19] . However, we must keep in mind that coagulation factor VIII is a glycoprotein whereas insulin does not contain any saccharidic components.
Additional investigations will be undertaken in order to determine whether conclusions drawn from the analysis of these 24 sera can be generalized to all insulin immunized patients and to establish potential correlation between anti-insulin IgG sub-class pattern and clinical course.
